ESMO TAT 2022 | Unmet needs in glioblastoma that EGFR inhibitor BDTX-1535 aims to address

Matthew Lucas, PhD, Black Diamond Therapeutics, Cambridge, MA, discusses problems that previous EGFR inhibitors have faced when being used for glioblastoma multiforme (GBM) that the development of BDTX-1535 aims to address. The three key challenges are the heterogeneity of GBM tumors, the ability to penetrate the brain, and the ability to irreversibly bind. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.